AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $48.11B, up 9.7% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $48.11B in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.11B | +9.7% |
| FY2024 | Dec 31, 2024 | $43.87B | +16.8% |
| FY2023 | Dec 31, 2023 | $37.54B | +17.5% |
| FY2022 | Dec 31, 2022 | $31.96B | +27.9% |
| FY2021 | Dec 31, 2021 | $24.98B | +17.2% |
| FY2020 | Dec 31, 2020 | $21.32B | +9.5% |
| FY2019 | Dec 31, 2019 | $19.46B | +13.5% |
| FY2018 | Dec 31, 2018 | $17.15B | -5.5% |
| FY2017 | Dec 31, 2017 | $18.15B | -3.9% |
| FY2016 | Dec 31, 2016 | $18.88B | -5.9% |
| FY2015 | Dec 31, 2015 | $20.06B | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.86B | +65.5% |
| Q2 FY2025 | Jun 30, 2025 | $11.98B | +98.8% |
| Q2 FY2024 | Jun 30, 2024 | $10.76B | +103.3% |
| Q2 FY2023 | Jun 30, 2023 | $9.46B | +98.7% |
| Q2 FY2022 | Jun 30, 2022 | $7.77B | +87.6% |
| Q2 FY2021 | Jun 30, 2021 | $6.03B | +47.0% |
| Q2 FY2020 | Jun 30, 2020 | $5.29B | – |
| Q2 FY2019 | Jun 30, 2019 | $4.76B | – |
| Q2 FY2018 | Jun 30, 2018 | $4.14B | – |
| Q2 FY2017 | Jun 30, 2017 | $4.10B | – |
See a number that looks wrong?